Core Viewpoint - Herbal Dispatch Inc. is planning a non-brokered private placement to raise up to $1,000,000, which will support its anticipated export growth and working capital needs [1][2]. Group 1: Private Placement Details - The company intends to issue up to 20,000,000 units at a price of $0.05 per unit, with each unit consisting of one common share and one-half common share purchase warrant [1]. - Each full warrant can be exercised for one common share at a price of $0.08 per share for a period of 24 months after the closing date [1]. - The closing of the private placement is expected before August 29, 2025, and is subject to regulatory approvals [3]. Group 2: Use of Proceeds - Proceeds from the private placement will be utilized for working capital to support the company's expected export growth [2]. Group 3: Company Overview - Herbal Dispatch operates leading cannabis e-commerce platforms and aims to provide high-quality cannabis products at affordable prices [4]. - The company's flagship marketplace, herbaldispatch.com, offers exclusive access to small-batch craft cannabis and various product formats [4].

Financial Data and Key Metrics Changes - Tilray achieved record annual revenue of $821 million, a 4% increase year over year on a constant currency basis, and $834 million, a 6% increase year over year [7][36] - The company reported a gross profit of $241 million, an 8% increase year over year, and the highest gross margin at 29%, up from 28% in the prior year [8][42] - A net loss for fiscal year 2025 increased to $2.2 billion, or $2.46 per share, compared to a loss of approximately $220 million in the prior year [43][44] Business Line Data and Key Metrics Changes - International cannabis revenue reached $22.4 million in Q4, up 71% year over year, with a full year growth of approximately 20% [7][13] - The Canadian cannabis revenue totaled $186 million, with a market share of 9.3% in the adult recreational segment [18][19] - Beverage revenue increased by 19% year over year, but was impacted by SKU rationalization, resulting in a revenue reduction of $20 million [25][40] Market Data and Key Metrics Changes - The international cannabis business saw significant growth, particularly in Germany, where revenue grew 134% year over year in Q4 [14][17] - The Canadian market is stabilizing, with more retail stores opening and consumers shifting from the illicit market [66][67] - The wellness segment reported net revenue of over $60 million, representing a 9% growth year over year [31][32] Company Strategy and Development Direction - The company is focused on solidifying its global leadership in cannabis and expanding its beverage and wellness business through innovation and strategic acquisitions [6][11] - Tilray aims to strengthen its balance sheet through further strategic debt restructuring in fiscal year 2026 [8][48] - The company is well-positioned to expand its market share across Europe, supported by vertically integrated operations and EU GMP cultivation facilities [14][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, despite the non-cash impairment charges, emphasizing confidence in the intrinsic value of assets and long-term strategy [10][45] - The company anticipates continued growth in international markets and is focused on addressing regulatory challenges to capitalize on opportunities [73][76] - Management highlighted the potential for regulatory reforms in Canada that could enhance market conditions and reduce excise taxes [67][68] Other Important Information - The company has reduced its debt by approximately $100 million and improved its net debt to EBITDA ratio to 0.3 times from 1.7 last year [8][48] - The beverage segment is undergoing a transition with the integration of craft brands and a focus on operational optimization [24][27] Q&A Session Summary Question: What is the current status of import rights and delays? - Management indicated that issues with legal permits in Portugal are being resolved, and they expect to see a pickup in shipments within the first and second quarters [61][62] Question: How is the Canadian market evolving? - Management noted that the Canadian market is stabilizing with more retail stores opening and consumers increasingly purchasing from legal sources rather than the illicit market [65][66] Question: What are the growth expectations for international markets next year? - Management highlighted that there are significant opportunities in Europe and other international markets, with plans for substantial growth built into their strategy [75][76]

Financial Data and Key Metrics Changes - Tilray achieved record annual revenue of $821 million, a 4% increase year over year on a constant currency basis, and $834 million, a 6% increase year over year [7][34] - The company reported a gross profit of $241 million, an 8% increase year over year, and the highest gross margin at 29%, up from 28% in the prior year [8][40] - A net loss for fiscal year 2025 increased to $2.2 billion, or $2.46 per share, compared to a loss of approximately $220 million in the prior year [41][50] Business Line Data and Key Metrics Changes - International cannabis revenue reached $22.4 million in Q4, up 71% year over year, with a full year growth of approximately 20% [7][14] - The beverage segment reported net revenue of $65.6 million in Q4, a 19% year-over-year increase, although impacted by SKU rationalization initiatives [24][38] - Wellness revenue grew by 9% to over $60 million, driven by the expansion of the Manitoba Harvest brand and new product innovations [29][30] Market Data and Key Metrics Changes - In Canada, Tilray maintained a 9.3% market share in the adult recreational segment, with a total cannabis revenue of $186 million for the fiscal year [18][12] - The international cannabis business showed significant growth, particularly in Germany, where revenue grew by 134% year over year in Q4 [15][12] - The U.S. beverage division generated approximately $240 million in sales, with a focus on expanding market share in the non-alcoholic beverage sector [13][28] Company Strategy and Development Direction - The company is focused on solidifying its global leadership in cannabis and expanding its beverage and wellness business through innovation and strategic acquisitions [6][12] - Tilray aims to strengthen its balance sheet through strategic debt restructuring and has reduced its net debt to EBITDA ratio to 0.3 times from 1.7 last year [9][41] - The company is optimistic about future growth opportunities in international markets, particularly in Europe and emerging markets [17][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategy despite recent non-cash impairment charges, emphasizing the intrinsic value of tangible assets and brand equity [11][43] - The Canadian cannabis market is stabilizing, with expectations of regulatory reforms that could enhance market conditions [17][65] - Management anticipates continued growth in international cannabis markets, particularly in Germany, Poland, and the UK, with significant plans for expansion [70][72] Other Important Information - The company implemented strategic initiatives that impacted revenue by approximately $35 million due to decisions aimed at enhancing margins and profitability [7][35] - The beverage business faced challenges due to softer consumer demand and unexpected distribution headwinds, but corrective actions are being taken to improve performance [24][26] - Tilray's wellness segment is expected to expand further in fiscal year 2026, focusing on better-for-you functional foods and beverages [31][30] Q&A Session Summary Question: What is the current status of importing rights and delays? - Management indicated that legal issues in Portugal are being resolved, and they expect to start shipping products soon, with an estimated $8 million in sales impacted by trapped shipments [60][61] Question: Can you elaborate on the Canadian market's equilibrium and price pressures? - Management noted that the Canadian market is stabilizing with more retail stores opening, leading to increased consumer preference for legal cannabis over illicit products, and potential regulatory changes could further enhance market conditions [63][65] Question: How should growth in international markets be viewed for next year? - Management expressed optimism about international growth, particularly in Germany and other European markets, with significant plans for expansion and a focus on medical cannabis [70][72]

Core Insights - Tilray Brands, Inc. reported a fiscal year net revenue of $821 million, with a constant currency revenue of $834 million, impacted by strategic decisions that affected revenue by $35 million [1][12] - The company achieved its second-highest consolidated adjusted EBITDA in history during Q4 [1] - International cannabis revenue surged by 71% in Q4 and 19% for the fiscal year, with Canadian cannabis maintaining the top revenue position [1][4] - Tilray Beverages and Tilray Wellness experienced revenue growth of 19% and 9%, respectively, for the fiscal year [1][11] Financial Performance - Fiscal year 2025 net revenue increased by 4% to $821.3 million compared to $788.9 million in the prior fiscal year [13] - Gross profit for the fiscal year rose by 8% to $240.6 million, with a gross margin of 29% [13] - Cannabis net revenue for fiscal 2025 was $249 million, down from $272.8 million in the previous year, primarily due to strategic margin preservation efforts [13][11] - Adjusted EBITDA for fiscal 2025 was $55 million, compared to $60.5 million in the prior fiscal year [13] Strategic Initiatives - The company is focusing on international growth, with a 19% increase in international cannabis revenue and a 112% growth in European cannabis revenue when excluding Australia [4][5] - Tilray has made strategic acquisitions in the beverage sector, acquiring four craft brands from Molson Coors to enhance its market presence [6] - The introduction of hemp-derived Delta-9 THC drinks in the U.S. is part of Tilray's strategy to innovate at the intersection of cannabis, beverages, and wellness [7] Balance Sheet and Liquidity - Tilray reported a strong balance sheet with $256 million in cash and marketable securities, and total debt repayments of approximately $100 million to date [2][8] - The net debt to trailing twelve months adjusted EBITDA ratio stands at 0.3x, indicating strong financial health [8] Future Outlook - For fiscal year 2026, the company expects adjusted EBITDA to be between $62 million and $72 million, representing growth of 13% to 31% compared to fiscal year 2025 [12][11] - The company anticipates significant growth opportunities in cannabis, beverage, and wellness sectors, particularly in Europe and emerging markets [3][4]

Canadian firm CEA Industries—which trades as VAPE on the Nasdaq—is up huge after revealing a $500 million raise to start a BNB treasury. https://t.co/IDckX8JK37 ...

Core Insights - The cannabis industry has seen a significant decline from $30 billion to approximately $4 billion, raising concerns for investors in marijuana stocks [1][2] - Federal reform is deemed necessary for the market to gain legitimacy, which historically has led to improved market momentum when such measures have been proposed [2] - Current market conditions have left investors uncertain, with some viewing the low prices as a potential buying opportunity for top marijuana stocks [3] Company Summaries - **Jushi Holdings Inc.**: A vertically integrated cannabis company involved in cultivation, processing, retail, and distribution for both medical and adult-use markets in the U.S. [4][5] - **Greenlane Holdings, Inc.**: Focuses on the development and distribution of cannabis accessories and lifestyle products across the U.S., Canada, Europe, and Latin America. Recently announced a partnership with JointCommerce for B2C e-commerce solutions [9][13] - **Cresco Labs Inc.**: Engaged in the cultivation and sale of retail and medical cannabis products. The company is undergoing a strategic restructuring, including the sale of its California operations to enhance its balance sheet and focus on high-margin markets [14][16]

Core Insights - Cannara Biotech Inc. reported record-breaking financial results for Q3 2025, showcasing significant growth in revenue, gross profit, and cash flow, reflecting the successful execution of its long-term business strategy [3][6][7]. Financial Highlights - Total revenues, net of excise taxes, increased to $27.3 million in Q3 2025, representing a 40% increase year-over-year [7][12]. - Gross profit before fair value adjustments rose to $12.1 million in Q3 2025, a 110% increase from $5.7 million in Q3 2024, with gross margin improving to 44% from 29% [6][12][29]. - Adjusted EBITDA reached a record high of $7.6 million in Q3 2025, a 173% increase compared to the prior year, with an adjusted EBITDA margin of 28% [7][12][29]. - Operating cash flow surged to $13.9 million, up 221% from the previous year, while free cash flow increased to $11.7 million, an 841% rise [7][12][29]. Operational Highlights - The company achieved a 26% yield improvement across its facilities, increasing annual production capacity from 39,500 kg to 50,000 kg, reaching its Fiscal 2026 target a year ahead of schedule [4][15]. - Cannara received acceptance for 5 SKUs for the upcoming launch of the vape category in Québec, representing 20% of all accepted in-store SKUs by the province [4][19]. Market Position - Cannara's gross cannabis revenues before excise taxes increased to $37.8 million in Q3 2025, a 44% increase from $26.2 million in Q3 2024, driven by market penetration and new product introductions [12][29]. - The company maintained a disciplined approach to scaling production, focusing on profitability while expanding its market share across Canada [17]. Debt Management - Cannara successfully reduced its interest rate on its BMO credit facility by 50 basis points, bringing the cost of debt below 6%, reflecting strong financial performance and effective capital management [7][44][45].

Inside Cannabis’ Willy Wonka Flavor Factory https://t.co/YUAWBgQ6IT https://t.co/YUAWBgQ6IT ...

Industry Overview - The cannabis industry has experienced a decline in overall projections, yet some companies are still achieving success in specific areas, suggesting potential for a market correction in marijuana stocks [1] - The current downtrend in marijuana stocks has been volatile, with brief moments of upward trading quickly followed by declines [1][2] Investment Sentiment - Investors are advised against chasing speculative patterns based on the hope of federal reform and continued profitability, as the risks remain high [2] - Despite the low sector performance, identifying top marijuana stocks for long-term investment is becoming increasingly attractive [2] Long-term Outlook - Long-term investing is a common strategy among those interested in marijuana stocks, driven by the industry's growth and popularity, which offers hope for future recovery [3] - The potential for recovery could serve as a significant turning point for many marijuana stocks [3] Company Highlights - **Ascend Wellness Holdings, Inc.**: Engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the U.S. Recently launched a revamped eCommerce ecosystem to enhance customer experience [4] - **FLUENT Corp.**: Cultivates and sells medical cannabis products across several states, including Florida and Texas [5] - **Ayr Wellness Inc.**: Involved in the cultivation and retail of cannabis products, recently amended a Limited Waiver Agreement related to financial reporting delays [9][7]

Core Insights - Cresco Labs (CRLBF) is divesting its California operations to streamline its business and improve profitability amid persistent challenges in the domestic cannabis market [1][3][10] - The decision reflects a broader industry trend where cannabis companies are reevaluating their presence in underperforming markets [4][11] Company Strategy - The divestiture is part of a strategic restructuring plan aimed at strengthening the balance sheet, increasing cash flow, and focusing on markets with higher margins and growth potential [3][10] - Despite the divestiture, the company will retain its premium FloraCal brand and continue its production and marketing across key domestic markets [5] Market Challenges - California, while the largest cannabis market, presents significant operational challenges such as intense price competition, illicit market activity, and high taxes, making profitability difficult [2][10] - Cresco's revenue is solely generated from the U.S., exposing it to the challenges of a heavily regulated domestic market [6] Financial Performance - The company has flagged potential revenue dips in Q2 due to operational disruptions related to Illinois' mandatory seed-to-sale system transition, with profitability under pressure from shrinking gross and EBITDA margins [7][8] - Loss estimates for 2026 and 2027 have widened over the past 60 days, indicating ongoing financial challenges [15] Competitive Landscape - Cresco faces stiff competition from peers like Curaleaf Holdings, Green Thumb Industries, and Tilray Brands, all pursuing similar strategies for expansion and cost optimization [11] - Competitors are also expanding internationally, which may provide them with an edge over Cresco, which remains focused on the saturated U.S. market [12]